| News

Noema Pharma raises 54 million Swiss francs

01.12.2020

The Basel-based pharmaceutical company Noema Pharma has raised a total of 54 million Swiss francs as part of a Series A financing round. This should help to advance the clinical development of drugs aimed at fighting rare neurological disorders.

Noema Pharma develops drugs to treat rare neurological disorders that arise on account of imbalanced neuronal networks. Clinical development can now be advanced for four relevant product candidates after Noema Pharma successfully closed a financing round by raising a total of 54 million Swiss francs, as detailed in a press release. In addition, the Basel-based pharma group Roche has now received a shareholding in Noema in exchange for rights to the four product candidates. These aim to combat “seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders”.

“The successful licensing of these exciting clinical-stage product candidates from Roche, together with our up-sized CHF 54 million Series A financing, will enable Noema to reach value-creating development milestones with all four products”, comments Luigi Costa, CEO of Noema, in the press release, before adding: “We are honored to have garnered continued support from our seed investor, Sofinnova Partners, and to have attracted Polaris Partners as a co-lead investor. We are equally pleased to welcome highly experienced specialist investors Gilde Healthcare, Invus and BioMed Partners”.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, and Darren Carroll, Partner at Polaris Partners, will both become members of the newly formed Board of Directors at Noema Pharma. While Papiernik underlined the work conducted by Noema up to this point that has aimed “to bring ground-breaking therapies to patients with debilitating neurological disorders”, Carroll, for his part, described the company as a “prime example of the exceptional pharma-grade assets Europe has to offer, along with a flourishing talent pool”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Zifo RnD Solutions coming to Basel
Basel Area Business & Innovation, Innovation, Invest

Zifo RnD Solutions coming to Basel

Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo...

Read More
Announcing the chosen ventures for the DayOne Accelerator (2020/2021)
Basel Area Business & Innovation, Innovation

Announcing the chosen ventures for the DayOne Accelerator (2020/2021)

The DayOne Accelerator ventures for 2020/21 have been chosen. Over 100 teams applied for the program which will run from...

Read More
«We will show the new product at the Olympic Games 2021 in Tokyo»
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

«We will show the new product at the Olympic Games 2021 in Tokyo»

The new Basel Area Business & Innovation Podcast offers exciting conversations with interesting interview partners. The first guest is surgeon...

Read More
Announcing the final winners of the i4Challenge 2020
Basel Area Business & Innovation, Innovation

Announcing the final winners of the i4Challenge 2020

The expert jury of the i4Challenge selected this year's winners. The solutions from the field of Industry 4.0 range from...

Read More
Patients stand to benefit from innovative tech project
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Patients stand to benefit from innovative tech project

The investment and innovation promotion agency Basel Area Business & Innovation is joining forces with several partners to realize a...

Read More
Boehringer Ingelheim acquires Basel’s NBE-Therapeutics
Basel Area Business & Innovation, Innovation, Invest

Boehringer Ingelheim acquires Basel’s NBE-Therapeutics

German pharma group Boehringer Ingelheim is to acquire the Basel life sciences company NBE-Therapeutics for €1.18 billion. NBE-Therapeutics specializes in...

Read More
1 2 3 38

Do you have a question? We'd like to hear from you.